Generic Injectables Market Size & Share | Global Trends 2021, 28
The generic injectables market is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021; it is expected to register a CAGR of 10.5% from 2021 to 2028.
Generic injectables are the bioequivalents of their branded counterparts and are not protected by patents. They are safe and effective as the innovator drugs since they have similar active ingredients, dosages, strength, qualities, form, etc.
The report offers insights and in-depth analysis of the generic injectables market, emphasizing various parameters such as market trends, technological advancements, and market dynamics; it also provides the competitive landscape analysis of leading market players and the impact of the COVID-19 pandemic on the market across all major regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. As per the recent WHO statistics, the US is the world's worst-affected country due to the pandemic with the highest number of cases. The high number of COVID cases has negatively impacted the economy of the US, and consequently that of North America. There has been a decline in overall business activities and growth of various industries operating in the region.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Generic Injectables Market: Strategic Insights
Generic Injectables Market
-
CAGR (2021 - 2028)
10.5%
-
Market Size 2021
US$ 74.74 Billion
-
Market Size 2028
US$ 150.65 Billion
Market Dynamics
GROWTH DRIVERS
- Increase in generic drug production and sales
- Rising demand for generic injectables in the pharmaceutical industry
FUTURE TRENDS
- Growth in the demand for cost-effective medications
- availability of biosimilar and generic injectables
- Rising demand in chronic disease treatments.
OPPORTUNITIES
- Growth in generic drug demand globally
- Expanding opportunities for generic injectables in emerging pharmaceutical markets
Key Players
- Astrazeneca
- Baxter International Inc
- Biocon
- Fresenius SE Co KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson Johnson Services Inc
- Lupin Ltd
- Merck Co Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product Type
- Large Molecule Injectables and Small Molecule Injectables
Container Type
- Vials
- Premix
- Prefilled Syringes
- Ampoules
Application
- Oncology
- Infectious Diseases
- Cardiology
- Diabetes
- Immunology
Route of Administration
- Intravenous
- Intramuscular
- Subcutaneous
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Generic Injectables Market: Strategic Insights
-
CAGR (2021 - 2028)10.5% -
Market Size 2021
US$ 74.74 Billion -
Market Size 2028
US$ 150.65 Billion
Market Dynamics
- Increase in generic drug production and sales
- Rising demand for generic injectables in the pharmaceutical industry
- Growth in the demand for cost-effective medications
- availability of biosimilar and generic injectables
- Rising demand in chronic disease treatments.
- Growth in generic drug demand globally
- Expanding opportunities for generic injectables in emerging pharmaceutical markets
Key Players
- Astrazeneca
- Baxter International Inc
- Biocon
- Fresenius SE Co KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson Johnson Services Inc
- Lupin Ltd
- Merck Co Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Large Molecule Injectables and Small Molecule Injectables
- Vials
- Premix
- Prefilled Syringes
- Ampoules
- Oncology
- Infectious Diseases
- Cardiology
- Diabetes
- Immunology
- Intravenous
- Intramuscular
- Subcutaneous
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
However, there was an unusual demand for Remdesivir, an antiviral medicine used to treat patients, when the outbreak was at its peak. Thus, manufacturers in the generic injectables market are now prepared for the future as they focus on keeping adequate stock for keeping supply chain operations unaffected dur to any type of vulnerabilities. Gilead Sciences and other big pharma companies, for example, have reduced the prices of their generic versions of remdesivir considerably. Companies are utilizing government programs and financing schemes offered by the BFSI industries to streamline their operations. In May 2020, the US government entered into an agreement, worth US$ 812 million, with a group of American generic medicine manufacturers, with the goal of bolstering the country's drug supply amid the global COVID-19 pandemic.
Furthermore, the pandemic strained pharmaceutical industries globally, interrupting and delaying supply of various critical drugs. Many market players came to rescue with immediate actions. For instance, in January 2021, Civica Rx teamed up with the brand-new Phlow Corp. in an effort to support drug manufacturing in the US and supply critical medications to hospitals fighting the pandemic. Civica invested US$ 124.5 million in the construction of a sterile injectable manufacturing facility in Petersburg, Virginia, which rose to prominence last year owing to a large government contract to produce COVID-19-related drugs.
Based on region, the generic injectables market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.
Market Insights
High Demand for Affordable Drugs Drives Generic Injectables Market
High Demand for Affordable Drugs Drives Generic Injectables Market
Innovator drugs are expensive owing to high investments made in the research & development of molecules; these drugs are specifically unaffordable for a large share of the population in developing countries. However, generic drugs are affordable and provide greater access to healthcare. As published by the Association for Accessible Medicines (AAM), the average primary copay (the amount set by the insurance plans) of a generic drug is US$ 6.06 and US$ 40.30 for branded drugs. This fact indicates the falling prices of generic medicines by at least ~7%. According to the American Association of Retired Person (AARP), branded drug prices continue to increase at a pace that is 100-times greater than inflation. Moreover, as mentioned by the USFDA, 9/10 prescriptions filled in the US are for generic drugs. Additionally, the generic drug’s average manufacturer prices (AMP) are ~39% lower than the branded drug’s AMP. For instance, as published by Association for Accessible Medicines (AAM), 93% of generic prescriptions are filled for US$ 20 or less. The facts mentioned above boost the demand and availability of generic injectables, thus driving the entry of more players into the generic injectables market.
Further, low prices of generic injectables contribute to greater and effective chronic illness treatments. As per the World Health Organization (WHO), ~422 million people worldwide were diabetic in 2021. Generic injectables such as insulin injections offer immediate solutions for such ailments, alongside ensuring affordable treatments in developing countries.
Product Type-Based Insights
Based on product type, the generic injectables market is segmented into large molecule injectables and small molecule injectables. In 2021, the large molecule injectables segment accounted for a greater market share. The market position of this segment is credited to a surge in the adoption of biologics in the healthcare sector, and the progress of monoclonal antibody and antibody-drug conjugates (ADCs) into the drug development.
Container Type-Based Insights
Based on container type, the generic injectables market is segmented into vials, premix, prefilled syringes, ampoules, and others. The vials segment is likely to dominate the market in 2021.
Application-Based Insights
The generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. The oncology segment is likely to hold the largest share of the market in 2021. An increase in cancer incidences and rise in the launch of drugs is anticipated drives the growth of the oncology market segment.
Generic Injectables Market Report Scope
Report Attribute
Details
Market size in 2021
US$ 74.74 Billion
Market Size by 2028
US$ 150.65 Billion
Global CAGR (2021 - 2028)
10.5%
Historical Data
2019-2020
Forecast period
2022-2028
Segments Covered
By Product Type - Large Molecule Injectables and Small Molecule Injectables
By Container Type - Vials
- Premix
- Prefilled Syringes
- Ampoules
By Application - Oncology
- Infectious Diseases
- Cardiology
- Diabetes
- Immunology
By Route of Administration - Intravenous
- Intramuscular
- Subcutaneous
Regions and Countries Covered
North America - US
- Canada
- Mexico
Europe - UK
- Germany
- France
- Russia
- Italy
- Rest of Europe
Asia-Pacific - China
- India
- Japan
- Australia
- Rest of Asia-Pacific
South and Central America - Brazil
- Argentina
- Rest of South and Central America
Middle East and Africa - South Africa
- Saudi Arabia
- UAE
- Rest of Middle East and Africa
Market leaders and key company profiles
- Astrazeneca
- Baxter International Inc
- Biocon
- Fresenius SE Co KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson Johnson Services Inc
- Lupin Ltd
- Merck Co Inc
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 74.74 Billion |
Market Size by 2028 | US$ 150.65 Billion |
Global CAGR (2021 - 2028) | 10.5% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Product Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Route of Administration-Based Insights
Based on the route of administration, the generic injectables market has been categorized into intravenous, intramuscular, subcutaneous, and others. The intravenous segment held the largest market share in 2021.
The generic injectables market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide.
By Geography
North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- UK
- Spain
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Australia
- Rest of APAC
Middle East & Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
Company Profiles
- Astrazeneca
- Baxter International, Inc.
- Biocon
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Pfizer, Inc
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Container Type, Application, and Route of Administration, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Global generic injectables market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for generic injectables market. The US is estimated to hold the largest share in the generic injectables market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for generic injectables accounting fastest growth of the region during the coming years.
The oncology segment dominated the global generic injectables market and accounted for the largest revenue of 21.62 Bn in 2021.
Astrazeneca, Baxter International, Inc., Biocon, Fresenius SE & Co., KGaA, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin, Ltd., Merck & Co., Inc., Mylan N.V., Pfizer, Inc. are among the leading companies operating in the global generic injectables market
Generic Injectables are safe and effective innovator bio-equivalent drugs of their branded counterparts which are not protected by drug patents. They have a similar ingredient, dosage, strength, quality, form, etc.
High demand for affordable drugs is one of the most significant factors responsible for the overall market growth.
Based on product type, large molecule injectables took the forefront leaders in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The List of Companies - Generic Injectables Market
- Astrazeneca
- Baxter International, Inc.
- Biocon
- Fresenius SE & Co. KGaA
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Merck & Co., Inc.
- Mylan N.V.
- Pfizer, Inc.